Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Lowers Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska maintains an Overweight rating on Abeona Therapeutics (NASDAQ:ABEO) but lowers the price target from $28 to $21.
May 16, 2024 | 3:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cantor Fitzgerald maintains an Overweight rating on Abeona Therapeutics but lowers the price target from $28 to $21.
The lowered price target from $28 to $21 suggests a less optimistic outlook for Abeona Therapeutics, which could negatively impact the stock price in the short term despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100